AGENUS INC — Director's Dealing 2010

Mar 11, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANTIGENICS INC /DE/ (AGEN)
CIK: 0001098972
Period of Report: 2010-03-10

Reporting Person: ARMEN GARO H (Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-03-10	Common Stock	A	231579	$0.77	Acquired	1683483	Direct
2010-03-11	Common Stock	S	87628	$0.7875	Disposed	1595855	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12655941	Indirect

Footnotes

F1: Represents settlement of restricted stock granted on March 10, 2010 in lieu of an annual cash bonus for 2009 performance.

F2: Represents only shares sold to cover minimum federal, state and local tax withholding requirements upon the vesting of the restricted shares granted in lieu of an annual cash bonus for 2009 performance.

F3: Dr. Armen is the General Partner of Armen Partners LP. As of the date of this report Armen Partners owns a total of 1,507,667 shares of Antigenics Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Armen Partners and disclaims beneficial ownership except to the extent of his pecuniary interest therein. Dr. Armen is also CEO, Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which, as of the date of this report, owns 11,154,274 shares of Antigenics Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims benficial ownership except to the extent of his pecuniary interest therein.